Subtype
Male Reproductive System Carcinoma
CI-CAN-00003134Explore in graph →
450 active trials16 approved drugs20 evidence items
- NCIt
- C181196
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003134Explore in graph →
Clinical trials
1,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (190)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06250244 | 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 12 | Peking Union Medical College HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT05116579 | Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) | unknown | — | 30 | Sun Yat-sen UniversityOTHER | 1 | Sep 5, 2024 | clinicaltrials |
| NCT06237491 | The Safety and Dosimetry Study of 177Lu-LNC1003 Injection | unknown | Phase 1 | 12 | Yantai LNC Biotechnology Singapore PTE. LTD.INDUSTRY | 0 | Jul 24, 2024 | clinicaltrials |
| NCT05613738 | 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | N/A | 9 | Peking Union Medical College HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06227156 | Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT05458544 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application(LUCIDA) | unknown | Phase 1 / Phase 2 | 26 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05579184 | [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application_2(LUCIDA_2) | unknown | Phase 2 | 20 | FutureChemINDUSTRY | 1 | Apr 29, 2024 | clinicaltrials |
| NCT06387238 | Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer | unknown | N/A | 150 | Peking University First HospitalOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT03700099 | Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide | unknown | Phase 2 | 30 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT02266745 | A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | unknown | Phase 2 | 109 | Promontory Therapeutics Inc.INDUSTRY | 2 | Apr 5, 2024 | clinicaltrials |
| NCT06344715 | Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. | unknown | Phase 1 | 78 | SL VAXiGENINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06251492 | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) | unknown | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT05787535 | HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor | unknown | Phase 1 | 17 | HRYZ Biotech Co.INDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT02935205 | Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 38 | Mamta ParikhOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT04097002 | First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | unknown | Phase 1 / Phase 2 | 24 | Orca Therapeutics B.V.INDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT01949337 | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | unknown | Phase 3 | 1,311 | Alliance for Clinical Trials in OncologyOTHER | 3 | Sep 28, 2023 | clinicaltrials |
| NCT05919524 | SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer(SAFO) | unknown | N/A | 27 | Almudena ZapateroOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05558956 | Total Body PET-CT Imaging of Prostate Cancer Using Illuccix | unknown | Early Phase 1 | 100 | BAMF HealthOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05955209 | Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC) | unknown | Phase 2 | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jul 21, 2023 | clinicaltrials |
| NCT01913717 | Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion | unknown | N/A | 65 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02672449 | Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer | unknown | N/A | 65 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03381326 | CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.(IRSTB030) | unknown | — | 104 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT05607693 | A SHR3680 QT/QTc Study on Castration-Resistant Prostate Cancer Subjects | unknown | Phase 1 | 52 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 15, 2023 | clinicaltrials |
| NCT05823402 | Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study)(SPECTacular) | unknown | N/A | 30 | BAMF HealthOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03774901 | Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma(PULSE) | unknown | Phase 2 | 32 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Apr 21, 2023 | clinicaltrials |
| NCT05533203 | Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) | unknown | Phase 1 | 24 | Shanghai Humantech Biotechnology Co. LtdINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT02446366 | Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery | unknown | N/A | 24 | University of Southern CaliforniaOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT04833517 | Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) | unknown | — | 500 | Universität des SaarlandesOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05167175 | The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | unknown | Phase 2 | 30 | Hongqian GuoOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03601143 | Liquid Biopsy-based Detection of Resistance to Targeted Therapy in Prostate Cancer Patients(PEARL) | unknown | — | 120 | Technical University of MunichOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT03692663 | Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer | unknown | Early Phase 1 | 9 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 1, 2022 | clinicaltrials |
| NCT03780075 | Lu177-EB-PSMA617 Radionuclide Treatment in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 1 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05327621 | Pamiparib in mCRPC With HRD or BRCA1/2 Mutation | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT05262608 | The Study of Olaparib in Newly Diagnosed mCRPC Patients With HRR Gene Mutation(PROspect) | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05224024 | Retzius-sparing Technique in Robotic-assisted Radical Prostatectomy | unknown | N/A | 80 | Ankara UniversityOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT05188911 | Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial | unknown | — | 30 | Fudan UniversityOTHER | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02739659 | Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer | unknown | N/A | 73 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Nov 19, 2021 | clinicaltrials |
| NCT04851639 | The Wolverhampton Assessment Tool, a Tool for Patient-reported Wellbeing in the Context of Prostate Cancer(WATapp) | unknown | N/A | 50 | University of WolverhamptonOTHER | 1 | Oct 5, 2021 | clinicaltrials |
| NCT03305224 | The Combination Therapy With Ra-223 and Enzalutamide(CORE-OCU) | unknown | Phase 2 | 10 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT04984395 | Improving Diagnosis and Treatment of Metastatic Advanced Prostate Cancer(IDT) | unknown | — | 50 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04192890 | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer | unknown | N/A | 12 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT03431753 | Early and Accurate Detection of Prostate Cancer in General Practice | unknown | N/A | 3,000 | Aarhus University HospitalOTHER | 1 | May 4, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03943602 | Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)(CaboPen) | unknown | Phase 2 | 37 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04699344 | A Prospective, Single-centre，Single-blinded Study of PROUD for Prostate Carcinoma Diagnosis | unknown | — | 500 | Qilu Hospital of Shandong UniversityOTHER | 1 | Jan 7, 2021 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Dec 11, 2024source: clinicaltrials